Top Injectable Manufacturer in Kyrgyzstan – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 2 days ago
- 10 min read
Last Updated: August 23, 2026
TL;DR: Medicines in the Kyrgyz Republic are regulated by the Department of Medicines and Medical Devices under the Ministry of Health (ДЛСиМИ), constituted by Government Resolution No. 227 of 30 April 2020 — not the older Department of Drug Provision and Medical Equipment name still repeated by most consultancies. The governing statute is Law No. 13 of 12 January 2024 on the Circulation of Medicines, amended through 3 November 2025, with the registration procedure set by Cabinet Resolution No. 136 of 7 March 2023. Kyrgyzstan has been an EAEU member since 12 August 2015, so registration runs on EAEU Council Decision No. 78 of 3 November 2016 and an EAEU CTD whose Module 1 is region-specific. Decision No. 34 of 22 May 2025, in force since 21 June 2025, lets a manufacturer without an EAEU GMP certificate register on its home-country GMP certificate plus the paragraph 30 package and confirm EAEU GMP within three years. Registration takes 180 calendar days, or 20 on the accelerated route for WHO-prequalified products. Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling on ISO Class 5 aseptic lines, exporting to 30+ countries, and supplying CTD/ACTD dossiers with ICH Q1A(R2) stability data.
Key Takeaways
India is already Kyrgyzstan's number one pharmaceutical supplier. On Kyrgyzstan's own UN Comtrade returns — direct reporting, not mirror data — India supplied USD 43.9 million of the USD 273.7 million of HS Chapter 30 imports in 2025, a 16.0% share, ahead of Türkiye at 11.8% and Russia at 7.6%. India took the top spot from Russia in 2023 and has held it since, while Russia's share fell from 18.0% in 2022. In antibiotic dosage forms India's share is 43.1%.
The EAEU GMP obligation is deferrable, not avoidable. Under EAEU Council Decision No. 34 of 22 May 2025, in force since 21 June 2025, a site without an EAEU GMP certificate may register on the strength of its home-country GMP certificate plus the additional package in paragraph 30 of the Registration Rules, then has three years from registration to pass an EAEU GMP inspection. The Kyrgyz regulator states paragraph 30 now has permanent status; missing the three-year window is grounds for refusal or for suspension of the registration certificate.
The pathway is proven and the price is published. Four Indian manufacturers already hold Kyrgyz-issued EAEU GMP certificates. The tariff approved on 28 July 2025 is KGS 333,036 (about USD 3,808) for a medicines-manufacturer inspection, plus KGS 99,876 for each additional production line, with laboratory testing, travel, visas, per diems and interpreter costs payable separately by the applicant — and a domestic Kyrgyz plant pays 10% of the same fee.
The demand case is a shortage case, not a forecast. The Ombudsman documented roughly 80 missing medication types at the National Center for Oncology and Haematology, deliveries arriving only in November during 2024, and just 1.6% of the requested funding volume supplied by August 2025. Kyrgyzstan also sits on WHO's list of 30 high MDR/RR-TB burden countries, with 22% MDR/RR-TB among new pulmonary cases and TB treatment coverage of only 43%.
Introduction: Why an Injectable Manufacturer in Kyrgyzstan Must Work to EAEU Rules
The Kyrgyz Republic had a population of 7,343,064 in 2025 on World Bank figures, current health expenditure of USD 96.65 per person in 2023 at 4.50% of GDP, out-of-pocket spending at 42.26% of the total, and 3.73 hospital beds per 1,000 people. It is a small market that imports almost everything it uses: the Ministry of Economy and Commerce put import dependence at around 96% in June 2026, with roughly 30 medicine manufacturers and a pharmaceutical industry amounting to about 0.1% of industrial output. The trade data is unusually good because Kyrgyzstan reports directly to UN Comtrade. HS Chapter 30 imports reached USD 273.7 million in 2025, up 14.8% on the year, of which USD 241.5 million — 88.2% — was finished dosage forms. Imports of bulk, non-dosage-form product in 2024 came to USD 4,884. This is a finished-dosage-form market, full stop.
The defining structural fact is EAEU membership, held since 12 August 2015. Registration runs on EAEU Council Decision No. 78 of 3 November 2016 and on an EAEU CTD whose Module 1 is region-specific rather than plain ICH. Article 20 of the 2014 EAEU medicines agreement required nationally registered products to be brought into conformity with EAEU requirements by 31 December 2025, and that filing gate has now closed: conversion applications had to be with the chosen reference state by that date. Decision No. 34 of 22 May 2025 softened the consequences but did not abolish the deadline. For a new Indian entrant the practical consequence is simple and worth stating clearly — there is no national shortcut left, and any injectable manufacturer in Kyrgyzstan filing today registers under EAEU rules from the outset.
What Sets a World-Class Injectable Manufacturer in Kyrgyzstan Apart
EAEU GMP is the hinge on which everything turns, and the good news is that it is a deadline rather than a gate. Under Decision No. 34, where an EAEU GMP certificate is absent an applicant may submit the manufacturer's home-country GMP certificate together with the additional document package specified in paragraph 30 of the Registration Rules, and must then confirm conformity of its sites to EAEU GMP within three years of registration; the Kyrgyz regulator has confirmed that paragraph 30 now carries permanent status, and that failure within the window is grounds for refusal or for suspension or cancellation of the certificate. Inspections are carried out by the Pharmaceutical Inspectorate within the Department, against EAEU GMP and GDP rules, by inspectors entered on the EAEU register. The published tariff, approved 28 July 2025, is KGS 333,036 per manufacturer inspection and KGS 99,876 for each additional line or partial-process site, with travel, per diems, interpreting and laboratory testing billed separately.
The cost of not holding EAEU GMP is where the economics bite. Under Article 23(1)(2) of Law No. 13 of 2024, registered imported medicines escape batch-by-batch Kyrgyz quality assessment only where the distributor holds a valid GDP certificate and the manufacturing site held a valid EAEU GMP or ICH-region GMP certificate when the batch was made. India falls into neither category, so until EAEU GMP is in hand every consignment faces applicant-funded quality assessment, and non-compliant consignments must be re-exported or destroyed. Article 24(1) then requires re-inspection at least every three years. Set against that, the accelerated route is genuinely generous: 20 calendar days rather than 180 for products on the WHO prequalified list and for those registered by the US FDA, the EMA centralised procedure, Japan's PMDA, Swissmedic or the UK MHRA. Confirmation of registration runs 90 days and variations 50.
Quality Systems Behind Every Batch We Ship to Kyrgyzstan
Product leaves the Gujarat site through an ISO Class 5 aseptic core, Grade A filling under Grade B background, with routine media fills qualifying the aseptic process and continuous viable and non-viable environmental monitoring. Batch release covers sterility by the pharmacopoeial method, bacterial endotoxin by LAL, Karl Fischer moisture determination on lyophilised presentations, HPLC and GC for assay, related substances and residual solvents, sub-visible and visible particulate matter, and container closure integrity, all written to USP, BP, IP or EP monographs. This matters concretely for a Kyrgyz filing, because the registration dossier calls for product samples together with reference standards of the active substances and their related impurities and any specific reagents, in quantities sufficient for at least three full analyses. The analytical package has to travel with the file.
The documentation package is built to be filed. Modules 1 to 5 in EAEU CTD format, with the electronic dossier following EEC Board Decision No. 79 of 30 June 2017; the quality normative document; packaging mock-ups in the official and state languages and a patient leaflet in both Russian and Kyrgyz, reflecting EAEU Decision No. 76 as amended in September 2022. Two local obligations are easy to underestimate. Pharmacovigilance requires a Pharmacovigilance System Master File and a Qualified Person who must reside in Kyrgyzstan and be contactable 24 hours a day, with any change notified within three working days — a standing local cost, not a one-off. And serialisation is mandatory: Data Matrix marking and registration in the traceability system operated by the Department, with Essential Medicines List products in scope since 1 November 2023. Document legalisation, at least, is straightforward: Kyrgyzstan has been an Apostille Convention party since 31 July 2011 and neither India nor Kyrgyzstan objected to the other's accession, so Indian certificates are apostilled rather than consularised.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Kyrgyzstan for Global Buyers
Start with the trade position, because it removes the need for advocacy. On Kyrgyzstan's own customs returns to UN Comtrade, India supplied USD 43,915,721 of pharmaceuticals in 2025, 16.0% of the USD 273.7 million total, ahead of Türkiye at USD 32.4 million and Russia at USD 20.7 million; India holds 43.1% of the antibiotic dosage-form line specifically. One figure deserves attention from any Kyrgyz buyer. Kyrgyzstan records USD 43.9 million of Indian-origin pharmaceuticals arriving in 2025, while India records only USD 19.25 million of pharmaceutical exports to Kyrgyzstan — a gap of about 2.28 times, far too large to be a CIF-versus-FOB effect. The most plausible reading is origin-versus-destination accounting: roughly half of India's real presence reaches Bishkek through distributors in the Gulf, Kazakhstan, Türkiye or Russia. Buying from the manufacturer directly removes that layer, and with it the margin and the traceability gap that come with it.
Then the routes to market, of which three are live. Kyrgyzpharmacia, the state enterprise created in March 2023, centrally procures 191 international non-proprietary names under Ministry of Health Order No. 1 of 1 January 2026 and delivered roughly KGS 6.2 billion, about USD 71 million, in 2025; its procurement campaign for 2027 opened with bid opening on 24 August 2026, and manufacturers are invited alongside official representatives and suppliers. The Additional Drug Package administered by the Mandatory Health Insurance Fund, governed by Cabinet Resolution No. 299 of 30 May 2025, reimburses 50% for insured patients and 90% for State Guaranteed Benefits Package categories, with a 2026 budget of KGS 710.3 million and a reimbursement list refreshed at least twice a year. And the Global Fund grant to Kyrgyzstan, where UNDP is Principal Recipient, carries a 2026 to 2028 allocation of USD 21.8 million; that channel requires WHO prequalification, stringent-regulatory-authority approval or Expert Review Panel status as its quality gateway.
The demand is documented and the negatives are real, so take both. GLOBOCAN 2024 estimates 8,902 new cancers and 5,139 cancer deaths a year, led by breast at 1,218 cases and stomach at 1,076, while the national registry recorded 6,651 new malignant neoplasms in 2024 with more than 40% presenting late and five-year survival at 34.2%. On tuberculosis, Kyrgyzstan sits on WHO's 30 high MDR/RR-TB burden list: 22% of new pulmonary cases and 49% of previously treated cases are MDR or rifampicin-resistant, against an estimated 2,600 incident MDR/RR-TB cases and treatment coverage of 43%. Now the honest negatives. India lost its EAEU developing-country tariff preference in October 2021, so Indian medicines pay the full MFN rate while Kazakh, Russian and Belarusian product enters duty-free — and on heavy, low-value infusion fluids Kazakhstan ships at about USD 5.25 per kilogram against India's USD 36.28, which means Indian large-volume parenterals are not obviously competitive even though antibiotic and small-volume injectables clearly are. Domestic sterile capacity now exists, with a plant opened in September 2024 holding a framework agreement to supply 300 state hospitals, but its verified catalogue is saline, novocaine, lidocaine and magnesium sulfate only, and it does not appear on the EAEU GMP register. Finally, on payment: the som is convertible and there are no repatriation restrictions, so the risk is not currency control but correspondent banking and sanctions screening, which sharpened in 2026. Counterparty bank selection matters more than the choice of payment instrument.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified injectable manufacturer that can supply Kyrgyzstan?
Yes. Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, producing more than 100 injectable presentations — ampoules, vials, lyophilised powders for reconstitution and small-volume parenteral solutions — on ISO Class 5 aseptic fill-finish lines and exporting to more than 30 countries. For the Kyrgyz Republic the company supplies what a registration file needs: CTD- and ACTD-structured dossiers that map onto the EAEU CTD, ICH Q1A(R2) long-term and accelerated stability data, DMF and CEP references where the API source supports them, a Site Master File, executed batch records, and certificates of analysis to USP, BP, IP or EP monographs.
Does an Indian manufacturer need an EAEU GMP certificate before registering in Kyrgyzstan?
Not before registering, but within three years of it. EAEU Council Decision No. 34 of 22 May 2025, in force since 21 June 2025, allows an applicant whose site has no EAEU GMP certificate to file using the GMP certificate issued in the manufacturer's own country plus the additional document package specified in paragraph 30 of the Registration Rules. Conformity to EAEU GMP must then be confirmed within three years of registration, and the Kyrgyz regulator has confirmed paragraph 30 now has permanent rather than temporary status. Missing that window is grounds for refusal, or for suspension or cancellation of an existing registration certificate. Four Indian manufacturers already hold Kyrgyz-issued EAEU GMP certificates, so the route is well established.
How long does medicine registration take in Kyrgyzstan?
The statutory period is 180 calendar days for registration, running from confirmation of payment, with 90 days for confirmation of registration and 50 days for a variation to the dossier. There is also a 20-day accelerated procedure, and its scope is worth checking against your portfolio: it covers products on the WHO prequalified list, products registered by the US FDA, the EMA centralised procedure, Japan's PMDA, Swissmedic or the UK MHRA, orphan products, products procured through UN organisations that have an agreement with the Cabinet of Ministers, strategically important medicines, and domestically manufactured products. For an exporter, a WHO prequalification on even one molecule can turn a six-month registration into a three-week one.
Do Indian documents need an apostille or consular legalisation for Kyrgyzstan?
An apostille, which is the simpler of the two. Kyrgyzstan acceded to the Hague Apostille Convention on 15 November 2010, with entry into force on 31 July 2011, and neither India nor Kyrgyzstan lodged an objection to the other's accession. Indian public documents — a certificate of pharmaceutical product, a GMP certificate, a free-sale certificate or a notarised power of attorney to a local representative — can therefore be apostilled by the Indian Ministry of External Affairs and used in Kyrgyzstan without consular legalisation. Separately, note that the patient leaflet must be provided in both Russian and Kyrgyz, and packaging artwork in one or both.
Which injectables does Farbe Firma supply against Kyrgyz demand?
The range follows the documented burden. Oncology injectables and supportive care answer an estimated 8,902 new cancers a year and a chronic, officially documented shortage at the National Center for Oncology and Haematology, where roughly 80 medication types were reported missing. Anti-tuberculosis and second-line injectables speak to a country on WHO's 30 high MDR/RR-TB burden list with 22% resistance among new pulmonary cases. Antibiotic injectables are the category in which India already holds 43.1% of Kyrgyz imports. Anaesthetics, analgesics, obstetric emergency products and cardiovascular injectables round out the range, across ampoules, vials, lyophilised powders and small-volume parenterals.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments